Brought to you by 
Uriach, Organon develop inflammatory disorder therapies
21 Jul 2004
Executive Summary
Akzo Nobel NV's human health care business Organon USA (reproductive medicine, psychiatry, and anesthesia) and Spanish pharmaceutical company J. Uriach & Cia. SA's (focuses on inflammation) are collaborating to discover, develop, and commercialize therapeutics to treat inflammatory diseases, particularly rheumatoid arthritis.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Uriach, Organon develop inflammatory disorder therapies
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice